Der Nephrologe

, Volume 5, Issue 2, pp 126–132 | Cite as

Immunsuppression nach Herz- und Lungentransplantation

Aktueller Stand
Leitthema

Zusammenfassung

Die immunsuppressive Langzeittherapie nach Herz- und Lungentransplantationen basiert auf vier verschiedenen Gruppen an Immunsuppressiva: Calcineurininhibitoren (Ciclosporin oder Tacrolimus), Antimetaboliten (Azathioprin oder Mycophenolatmofetil), mTOR („mammalian target of rapamycin“)-Inhibitoren (Sirolimus oder Everolimus) und Kortikosteroiden. Die Mehrheit der Patienten nach Herz- oder Lungentransplantation erhalten eine Dreifachbehandlung, die aus einem Calcineurininhibitor, einem Antimetaboliten und Kortikosteroiden zusammengesetzt ist. In einigen Zentren wird zusätzlich eine Induktionstherapie verabreicht, die aus einer kurzen perioperativen Gabe von mono- oder polyklonalen Antikörpern besteht.

Schlüsselwörter

Herztransplantation Lungentransplantation Immunsuppression 

Immunosuppression after heart and lung transplantation

Current status

Abstract

Immunosuppression after heart and lung transplantation is generally based on four groups of immunosuppressive agents: calcineurin inhibitors (cyclosporin A or tacrolimus), antimetabolites (azathioprine or mycophenolate mofetil), mammalian target of rapamycin inhibitors (rapamycin or everolimus), and corticosteroids. Most patients after heart or lung transplantation are treated with a triple immunosuppressive regimen, consisting of a calcineurin inhibitor, an antimetabolite, and corticosteroids. In addition, some centers use induction therapy, consisting of the perioperative application of intravenous mono- or polyclonal antibodies, targeting activated host lymphocytes.

Keywords

Heart transplantation Lung transplantation Immunsuppression 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Alloway R, Steinberg S, Khalil K et al (2007) Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 83:1648–1651CrossRefPubMedGoogle Scholar
  2. 2.
    Auphan N, DiDonato JA, Rosette C et al (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286–290CrossRefPubMedGoogle Scholar
  3. 3.
    Barnard JB, Thekkudan J, Richardson S et al (2006) Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant 25:564–568CrossRefPubMedGoogle Scholar
  4. 4.
    Bonnefoy-Berard N, Revillard JP (1996) Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15:435–442PubMedGoogle Scholar
  5. 5.
    Chatenoud L, Ferran C, Reuter A et al (1989) Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med 320:1420–1421PubMedCrossRefGoogle Scholar
  6. 6.
    Christie JD, Edwards LB, Aurora P et al (2008) Registry of the international society for heart and lung transplantation: twenty-fifth official adult lung and heart/lung transplantation reportGoogle Scholar
  7. 7.
    Eisen HJ, Hobbs RE, Davis SF et al (2001) Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine – results at 24 months after transplantation. Transplantation 71:70–78CrossRefPubMedGoogle Scholar
  8. 8.
    Eisen HJ, Tuzcu EM, Dorent R et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847–858CrossRefPubMedGoogle Scholar
  9. 9.
    Grimm M, Rinaldi M, Yonan NA et al (2006) Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients – a large European trial. Am J Transplant 6:1387–1397CrossRefPubMedGoogle Scholar
  10. 10.
    Groetzner J, Kaczmarek I, Schulz U et al (2009) VENINAHTx-Investigators. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 87:726–733CrossRefPubMedGoogle Scholar
  11. 11.
    Hartwig MG, Snyder LD, Appel JZ 3rd et al (2008) Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant 27:547–553CrossRefPubMedGoogle Scholar
  12. 12.
    Hershberger RE, Starling RC, Eisen HJ et al (2005) Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352:2705–2713CrossRefPubMedGoogle Scholar
  13. 13.
    Keogh A, Richardson M, Ruvgrok P et al (2004) Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110:2694–2700CrossRefPubMedGoogle Scholar
  14. 14.
    Kobashigawa J, Miller L, Renlund D et al (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 66:507–515CrossRefPubMedGoogle Scholar
  15. 15.
    Kobashigawa JA, Tobis JM, Mentzer RM et al (2006) Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 6:993–997CrossRefPubMedGoogle Scholar
  16. 16.
    Korom S, Boehler A, Weder W (2009) Immunosuppressive therapy in lung transplantation: state of the art. Eur J Cardiothorac Surg 35:1045–1055CrossRefPubMedGoogle Scholar
  17. 17.
    Krasinskas AM, Kreisel D, Acker MA et al (2002) CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation 73:1339–1341CrossRefPubMedGoogle Scholar
  18. 18.
    Lindenfeld J, Miller GG, Shakar SF et al (2004) Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 110:3858–3865CrossRefPubMedGoogle Scholar
  19. 19.
    Mehra MR, Zucker MJ, Wagoner L et al (2005) A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24:1297–1304CrossRefPubMedGoogle Scholar
  20. 20.
    Meiser B, Kaczmarek I, Mueller M et al (2007) Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J Heart Lung Transplant 26:598–603CrossRefPubMedGoogle Scholar
  21. 21.
    Meiser BM, Pfeiffer M, Schmidt D et al (1999) Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 18:143–149CrossRefPubMedGoogle Scholar
  22. 22.
    Meiser B, Reichart B, Adamidis I et al (2005) First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 5:827–831CrossRefPubMedGoogle Scholar
  23. 23.
    Meiser BM, Groetzner J, Kaczmarek I et al (2004) Tacrolimus or cyclosporine: Which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 78:591–598CrossRefPubMedGoogle Scholar
  24. 24.
    Oyer P, Stinson E, Jamieson S et al (1983) Cyclosporine in cardiac transplantation: a 2 1/2 year follow-up. Transplant Proc 15:2546Google Scholar
  25. 25.
    Reichart B, Meiser B, Viganò M et al (2001) European multicenter tacrolimus heart pilot study: three year follow-up. J Heart Lung Transplant 20:249–250CrossRefPubMedGoogle Scholar
  26. 26.
    Stenton SB, Partovi N, Ensom MHH (2005) Sirolimus: The evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 44:769–786CrossRefPubMedGoogle Scholar
  27. 27.
    Taylor DO, Barr ML, Radovancevic B et al (1999) A randomized multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 18:336–345CrossRefPubMedGoogle Scholar
  28. 28.
    Teuteberg J, Shullo M, Zomak R et al (2008) Alemtuzumab induction facilitates steroid-free maintenance immunosuppression in human cardiac transplantation. J Heart Lung Transplant 27:201–202CrossRefGoogle Scholar
  29. 29.
    Teuteberg JJ, Shullo M, Zomak R et al (2008) Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant 22:730–737PubMedGoogle Scholar
  30. 30.
    Uber PA, Mehra MR (2007) Induction therapy in heart transplantation: is there a role? J Heart Lung Transplant 26:205–209CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Herzchirurgischen Klinik und PoliklinikKlinikum der Universität München/GroßhadernMünchenDeutschland

Personalised recommendations